Evidence map›Paper›PMID 32257287›Full record

ArticleNeuro-oncology practice2020

Impact of volume of irradiation on survival and quality of life in glioblastoma: a prospective, phase 2, randomized comparison of RTOG and MDACC protocols.

Narendra Kumar, Ridu Kumar, Suresh C Sharma, Anindya Mukherjee, Niranjan Khandelwal, Manjul Tripathi, Raviteja Miriyala, Arun S Oinam, Renu Madan, Budhi S Yadav and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06551909 (Radioimmunotherapy in Solid Tumors), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06551909 narecruitingnot on this mapstarted 2024, after this paper: background citation

Radioimmunotherapy in Solid Tumors (Aim 2- Stereotactic Neoadjuvant Radiotherapy for Glioblastoma)

TypeinterventionalSponsorIRCCS San RaffaeleRan2024 to 2027Enrolled30ConditionsGlioblastomaArmsNeoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Narendra KumarDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.
Ridu KumarDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.
Suresh C SharmaDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.
Anindya MukherjeeDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.
Niranjan KhandelwalDepartment of Radiodiagnosis, PGIMER, Chandigarh, India.
Manjul TripathiDepartment of Neurosurgery, PGIMER, Chandigarh, India.
Raviteja MiriyalaDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.ORCID 0000-0003-4283-046X
Arun S OinamDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.
Renu MadanDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.
Budhi S YadavDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.
Divya KhoslaDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.
Rakesh KapoorDepartment of Radiotherapy, PGIMER (Post-Graduate Institute of Medical Education and Research), Chandigarh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThough conformal partial-brain irradiation is the standard adjuvant treatment for glioblastoma, there is no consensus regarding the optimal volume that needs to be irradiated. European Organisation for Research and Treatment of Cancer (EORTC) and The University of Texas MD Anderson Cancer Center (MDACC) guidelines differ from the Radiation Therapy Oncology Group (RTOG) in their approach toward peritumoral edema, whereas RTOG and MDACC guidelines differ from EORTC in the concept of boost phase. A scarcity of randomized comparisons has resulted in remarkable variance in practice among institutions.

methodsFifty glioblastoma patients were randomized to receive adjuvant radiotherapy using RTOG or MDACC protocols. Apart from dosimetric and volumetric analysis, acute toxicities, recurrence patterns, progression-free survival (PFS), overall survival (OS), and quality of life (QoL) were compared using appropriate statistical tests.

resultsBoth groups were comparable with respect to demographic characteristics. Dosimetric analysis revealed significantly lower boost-phase planning treatment volumes and V60 Gy in the MDACC arm (chi-squared,

conclusionsUse of limited-margin MDACC protocol can potentially improve survival outcomes apart from QoL of glioblastoma patients, as compared with the RTOG protocol.

Indexed as

glioblastomalimited-margin radiotherapyMDACC guidelinesrandomized trialRTOG guidelines

Identifiers

PMID32257287
PMCPMC7104885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.